Revolution Medicines Inc
NASDAQ:RVMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (16), the stock would be worth $-54.54 (138% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -42.4 | $144.12 |
0%
|
| Industry Average | 16 | $-54.54 |
-138%
|
| Country Average | 21.9 | $-74.3 |
-152%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
28.4B USD | -42.4 | -25.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 23.6 | 87.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 21.8 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 24.1 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 33.9 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 20 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 35.6 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Revolution Medicines Inc
Glance View
Revolution Medicines Inc. is a clinical-stage biotechnology company dedicated to reinventing cancer therapy through the development of targeted therapies that specifically inhibit proteins known as RAS. Recognized as one of the most challenging targets in cancer treatment, RAS mutations are implicated in a majority of solid tumors, making breakthrough innovations in this area essential. The company’s lead product candidate, RMC-6236, aims to offer a novel approach for patients with advanced cancers driven by specific mutations. By leveraging a proprietary drug discovery platform, Revolution Medicines is distinctly positioned to advance its pipeline of drug candidates through clinical trials, focusing on delivering precision strategies in oncology that promise transformative outcomes. As a forward-thinking entity in the biotech space, Revolution Medicines is not just about addressing current market needs but is also strategically crafting partnerships and collaborations to bolster its research and development capabilities. The company envisions a future in which its targeted therapies can significantly improve survival rates and quality of life for cancer patients. Investors are drawn to Revolution Medicines not only for its pioneering science but also for its robust clinical development strategy and the potential for substantial market impact as it tackles one of the most prevalent health challenges in society today. With a focus on delivering shareholder value while addressing significant unmet medical needs, Revolution Medicines is positioning itself as a leader in the quest for effective cancer treatments.
